tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Buy Rating for Fulcrum Therapeutics: Promising Potential of Pociredir in Sickle Cell Disease Treatment
PremiumRatingsBuy Rating for Fulcrum Therapeutics: Promising Potential of Pociredir in Sickle Cell Disease Treatment
3M ago
H.C. Wainwright upgrades Fulcrum to Buy on sickle cell data
Premium
The Fly
H.C. Wainwright upgrades Fulcrum to Buy on sickle cell data
3M ago
Fulcrum Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
Premium
The Fly
Fulcrum Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
3M ago
Fulcrum Therapeutics initiated with Early-Stage Biotech at Goldman Sachs
PremiumThe FlyFulcrum Therapeutics initiated with Early-Stage Biotech at Goldman Sachs
3M ago
Fulcrum Therapeutics price target raised to $6 from $2 at BofA
Premium
The Fly
Fulcrum Therapeutics price target raised to $6 from $2 at BofA
4M ago
Cautious Outlook on Fulcrum Therapeutics Amid Safety Concerns and Narrowed Trial Focus
Premium
Ratings
Cautious Outlook on Fulcrum Therapeutics Amid Safety Concerns and Narrowed Trial Focus
4M ago
Cisco upgraded, CoreWeave downgraded: Wall Street’s top analyst calls
PremiumThe FlyCisco upgraded, CoreWeave downgraded: Wall Street’s top analyst calls
5M ago
Cantor upgrades Fulcrum to Overweight on sickle cell opportunity
Premium
The Fly
Cantor upgrades Fulcrum to Overweight on sickle cell opportunity
5M ago
Fulcrum Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
Premium
The Fly
Fulcrum Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100